Teva Must Surrender Generics To Get Cephalon: FTC
By Maria Chutchian ( October 7, 2011, 8:02 PM EDT) -- The Federal Trade Commission announced Friday it will require Teva Pharmaceutical Industries Ltd. to sell the rights to a generic cancer pain drug and generic muscle relaxant as conditions of its $6.8 billion acquisition of drug firm Cephalon Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.